舒林酸与阿托伐他汀在伴或不伴结直肠腺瘤的Apc+/Min-FCCC小鼠中的差异预防活性
本研究在6-8周龄雄性Apc+/Min-FCCC小鼠中比较舒林酸与阿托伐他汀的化学预防效果,发现基线无瘤小鼠经阿托伐他汀完全抑制微腺瘤形成(P=0.018),而荷瘤小鼠经舒林酸/阿托伐他汀联合治疗腺瘤多发性降低43%(P=0.049)。结论认为治疗开始时的肿瘤状态决定干预反应。
要点
- 基线无瘤小鼠经阿托伐他汀完全抑制微腺瘤形成,P=0.018。
- 荷瘤小鼠经舒林酸/阿托伐他汀联合治疗腺瘤多发性较未治疗荷瘤小鼠降低43%,P=0.049。
- 基线荷瘤小鼠的结直肠腺瘤多发性是基线无瘤小鼠的3.6倍,P=0.002。
核心结论
- 治疗开始时动物的肿瘤状态决定其对治疗干预的反应。
- 阿托伐他汀在无瘤小鼠中消除了微腺瘤。
- 舒林酸/阿托伐他汀在荷瘤小鼠中观察到的肿瘤抑制大于各单药所达到的效果。
研究设计与样本
- 雄性Apc+/Min-FCCC小鼠(6-8周龄)接受结肠镜检查,随后给予对照饲料或含舒林酸(300 ppm)、阿托伐他汀(100 ppm)或舒林酸/阿托伐他汀的饲料。
- 治疗14周后采集组织进行组织病理学分析,治疗7天后采集组织进行基因表达分析。
- 对SW480结肠癌细胞进行细胞周期分析,细胞经舒林酸、阿托伐他汀或两者联合处理。
主要发现
- 基线荷瘤且未治疗小鼠的结直肠腺瘤多发性是基线无瘤小鼠的3.6倍(P=0.002)。
- 阿托伐他汀完全抑制了基线无瘤小鼠中微腺瘤的形成(P=0.018),并改变了与干/祖细胞相关基因的表达。
- 荷瘤小鼠经舒林酸/阿托伐他汀治疗较未治疗荷瘤小鼠结直肠腺瘤多发性降低43%(P=0.049)。
- 舒林酸/阿托伐他汀显著增加Hoxb13和Rprm的表达,提示细胞周期调控在肿瘤抑制中的重要性。
- 舒林酸/阿托伐他汀处理SW480细胞导致细胞周期阻滞(G0/G1)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The response of subjects to preventive intervention is heterogeneous. The goal of this study was to determine if the efficacy of a chemopreventive agent differs in non-tumour-bearing animals versus those with colorectal tumours. Sulindac and/or atorvastatin was administered to Apc+/Min-FCCC mice with known tumour-bearing status at treatment initiation. DESIGN: Male mice (6-8 weeks old) underwent colonoscopy and received control chow or chow with sulindac (300 ppm), atorvastatin (100 ppm) or sulindac/atorvastatin. Tissues were collected from mice treated for 14 weeks (histopathology) or 7 days (gene expression). Cell cycle analyses were performed on SW480 colon carcinoma cells treated with sulindac, atorvastatin or both. RESULTS: The multiplicity of colorectal adenomas in untreated mice bearing tumours at baseline was 3.6-fold higher than that of mice that were tumour free at baseline (P=0.002). Atorvastatin completely inhibited the formation of microadenomas in mice that were tumour free at baseline (P=0.018) and altered the expression of genes associated with stem/progenitor cells. Treatment of tumour-bearing mice with sulindac/atorvastatin led to a 43% reduction in the multiplicity of colorectal adenomas versus untreated tumour-bearing mice (P=0.049). Sulindac/atorvastatin increased the expression of Hoxb13 and Rprm significantly, suggesting the importance of cell cycle regulation in tumour inhibition. Treatment of SW480 cells with sulindac/atorvastatin led to cell cycle arrest (G0/G1). CONCLUSIONS: The tumour status of animals at treatment initiation dictates response to therapeutic intervention. Atorvastatin eliminated microadenomas in tumour-free mice. The tumour inhibition observed with Sul/Atorva in tumour-bearing mice was greater than that achieved with each agent.
引用
- Chang WL, Jackson C, Riel S, et al. Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut. 2017. PMID: 29122850. doi:10.1136/gutjnl-2017-313942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。